1,721,073 research outputs found
La rapida adozione degli smartphones nel mercato italiano: rivisitare il TAM di Davis F. per interpretare l'accettazione da parte del consumatore
Full text linkDupilumab associated inflammatory arthritis: a literature review
No full text: Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper (Th)-17 driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively not well-known adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may be not promptly recognised, and is probably underestimated. Herein, we reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for AD, aiming to improve a rapid recognition, and thus a prompt treatment of these diseases
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus
No full textEosinophilic pustular folliculitis (EPF) (Ofuji disease) is a chronic, noninfectious pruritic cutaneous disorder of unknown etiology. No official guidelines are available for its treatment. Herein we present the case of a 59-year-old Caucasian man admitted to our outpatient clinic due to a generalized itchy skin rash characterized by papulo-pustules involving the face, trunk, and limbs. Histological examination supported the clinical diagnosis of EPF (Ofuji disease). The combination of low-dose oral indomethacin and topical tacrolimus ointment once a day led to a complete resolution of the lesions as well as associated symptoms in 8 weeks
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
No full textBimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab represents the latest anti IL-17 treatment available for the management of moderate to severe psoriasis. Bimekizumab safety and efficacy profiles were evaluated in four Phase III clinical trials, which evaluated bimekizumab versus placebo and ustekinumab (BE VIVID), versus placebo (BE READY), versus adalimumab (BE SURE), and versus secukinumab (BE RADIANT). Overall, bimekizumab displayed promising results in terms of both efficacy and safety, allowing reach PASI90 and PASI100 in short time (as early as week 4) and maintain it in the long term (52 weeks), with acceptable safety profile. Also, bimekizumab showed a rapid onset of response and a higher efficacy when compared to adalimumab, ustekinumab and secukinumab, with comparable safety profile. Herein, we carried out a comprehensive literature review of the available literature data about bimekizumab in the treatment of moderate to severe psoriasis
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study
No full textUp until now, real-life experiences on the efficacy of risankizumab in patients who had previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitor are not reported. We carried out a single-centre, retrospective study, to evaluate the efficacy, safety and tolerability of patients under risankizumab who previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitors in a real-life setting. A total of 8 patients were enrolled (4 men and 4 women, mean age 45.8 ± 14.3 years). Five of them (62.5%) had received ustekinumab, 7 (87.5%) at least one anti-IL17, and only one (12.5%) patient guselkumab. Secukinumab had been used in 5 (62.5%) cases, and ixekizumab in 4 (50.0%). Baseline mean PASI and BSA were 11.9 ± 5.5, and 22.9 ± 13.1, respectively, and 3.3±1.7 and 7.5 ± 5 (P<0.001 and P<0.01) at week 16. Mean baseline NAPSI (18.0 ± 8.5) reduced to 7 ± 1.4 at week 16. Palmo-plantar and scalp area showed a reduction of 67.5% and 99.9% at week 16, respectively. No AEs was reported. Real-life preliminary data show risankizumab as a promising therapeutic option in patients who failed anti-IL-17, anti-IL12/23 and even the other anti-IL-23 counterpart, guselkumab. This article is protected by copyright. All rights reserved
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting
No full textBackground: Eleven biologic drugs are currently approved for psoriasis management. Real-life studies are needed to guide clinicians in choosing a tailored-tail therapy. The aim of our retrospective study is to indirectly compare the efficacy and safety of ixekizumab and brodalumab in psoriasis patients.
Methods: A single-centre real-life retrospective study was performed enrolling moderate-to-severe psoriatic patients under biologic treatment with ixekizumab or brodalumab. For each patient, clinical and demographic data were collected and the effectiveness and safety of brodalumab and ixekizumab treatment were evaluated at weeks 4, 12 and 24. Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) were used for psoriasis severity.
Results: A total of 139 patients were included in the study: 98(70.5%) and 41(29.5%) patients received ixekizumab and brodalumab, respectively. Mean PASI and BSA significantly reduced at each follow up for both ixekizumab and brodalumab groups. Even if ixekizumab reached higher rates of PASI90 and PASI100 than brodalumab (PASI90: 43.8%vs39.0% PASI100: 20.4%vs17.1% at week4 and PASI90: 83.6%vs75.6% PASI100: 71.5%vs60.9% at week24), these results were not statistically significant. Adverse events, mainly mild, were registered in 25.5% of ixekizumab and 26.8% of brodalumab group, respectively. Discontinuation rate was higher for brodalumab (17.1%vs9.1%), without statistical significance.
Conclusion: Our study showed comparable efficacy and safety for ixekizumab and brodalumab
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study
No full textRecent major research advancements have significantly expanded our understanding of psoriasis' pathophysiology, resulting in the development of highly-effective, targeted therapies. Guselkumab is the first interleukin (IL)-23-inhibitor approved for the treatment of moderate-to-severe-psoriasis, providing a new therapeutical option for psoriasis. The aim of our study was to evaluate the efficacy of guselkumab in psoriatic patients who previously failed anti-IL-12/23 and/or anti-IL-17
Video and telephone teledermatology consultations during COVID‐19 in comparison: patient satisfaction, doubts and concerns
No full text
- …
